Anthem Biosciences profitability ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
Returns
19.5%19.5%
17.3%17.3%
22.6%22.6%
22.4%23.3%
Margins
39.6%39.3%
32.9%32.9%
39.1%38.8%
28.8%27.9%
29.8%29.8%
Additional
26.4%28.2%
19.5%19.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ANTHEM₹830.15

Anthem Biosciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABGLAXOAJANTPHARMIPCALABABBOTINDIAMEDANTAGLENMARKMcap ₹46,631 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity19.4519.45
Return on Assets17.2617.26
Return on Capital Employed22.5522.55
Return on Invested Capital23.3122.38
Margins
EBITDA Margin39.2539.60
Operating Margin32.9432.94
Pretax Margin38.8039.08
Net Income Margin27.8628.76
FCF Margin29.8129.81
Additional
Effective Tax Rate28.2026.40
Sustainable Growth Rate19.4519.45
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.